- Home
- GHG vs SLS Comparison
GHG vs SLS Comparison
Compare GHG & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHG
- SLS
- Stock Information
- Founded
- GHG 2004
- SLS 2012
- Country
- GHG China
- SLS United States
- Employees
- GHG N/A
- SLS N/A
- Industry
- GHG Hotels/Resorts
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- GHG Consumer Discretionary
- SLS Health Care
- Exchange
- GHG Nasdaq
- SLS Nasdaq
- Market Cap
- GHG 221.3M
- SLS 185.3M
- IPO Year
- GHG 2018
- SLS N/A
- Fundamental
- Price
- GHG $2.09
- SLS $1.91
- Analyst Decision
- GHG
- SLS Strong Buy
- Analyst Count
- GHG 0
- SLS 1
- Target Price
- GHG N/A
- SLS $7.00
- AVG Volume (30 Days)
- GHG 25.1K
- SLS 1.9M
- Earning Date
- GHG 09-19-2025
- SLS 08-12-2025
- Dividend Yield
- GHG 4.98%
- SLS N/A
- EPS Growth
- GHG N/A
- SLS N/A
- EPS
- GHG 0.15
- SLS N/A
- Revenue
- GHG $184,055,595.00
- SLS N/A
- Revenue This Year
- GHG $19.02
- SLS N/A
- Revenue Next Year
- GHG $8.26
- SLS N/A
- P/E Ratio
- GHG $13.54
- SLS N/A
- Revenue Growth
- GHG N/A
- SLS N/A
- 52 Week Low
- GHG $1.81
- SLS $0.77
- 52 Week High
- GHG $3.40
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- GHG 43.92
- SLS 57.67
- Support Level
- GHG $2.05
- SLS $1.75
- Resistance Level
- GHG $2.22
- SLS $2.01
- Average True Range (ATR)
- GHG 0.11
- SLS 0.13
- MACD
- GHG 0.00
- SLS 0.01
- Stochastic Oscillator
- GHG 57.14
- SLS 75.00
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.